Merck's Third Raise Is Real — the 2027 Bridge Is Not
Guidance up again on Electronics and Bio-Techne, but Mavenclad is falling faster and Pergoveris is drifting
MRK.DE · Earnings Call · 2026-11-12
The headline is strength; the mix is the story
Kai Beckmann's first Q3 as group CEO delivered the third guidance raise of 2026: organic sales growth now 3-4%, EBITDA pre EUR 6.2-6.4bn, EPS pre EUR 8.30-8.70. Group organic growth accelerated to 5.1% from 4.1% in Q2, with foreign exchange turning from a headwind into a 1.5 percentage point tailwind. But EBITDA pre grew only 0.8%, because Q3 2025 carried a EUR 60m priority review voucher gain plus a EUR 59m benefit from South American legislative changes. The quality of the beat therefore sits in the divisions, not the group P&L. The strategic direction sketched in May is now being executed: four high-growth segments (biomanufacturing, discovery and development, semiconductor manufacturing, targeted specialty and rare disease), portfolio surgery (Bio-Techne in, CDMO out, Silence in), and footprint investment from Daejeon to Sheboygan. The keyword deck says it plainly — Bio Techne acquisition is the top company keyword this quarter, CDMO business second, leverage ratio third. The old narrative anchor, Process Solutions, has dropped out of the top ranks — not because the business is weak, but because the story has moved from operations to capital allocation.Electronics is the upside surprise — and the biggest tape risk
Electronics organic growth accelerated to 13%, with Semiconductor Solutions up 19%. Ben Hein was explicit that “for the full year 2026, we expect this pricing effect to contribute roughly 2 percentage points to organic sales growth in Semiconductor Solutions” — Benjamin Hein, Executive · 2026-11-12 — a temporary raw-material pass-through, one-third in Q3 and two-thirds in Q4, expected to fade over 2027. The underlying driver is advanced-node capacity in logic and memory for AI. The raise to 10-11% organic from 6-9% is real, but it leans on a pricing tailwind management itself calls temporary, plus an eleventh consecutive quarter of year-over-year growth in semiconductor materials that is now well understood. Here is the tension: the global price tape has turned against the AI hardware complex. High bandwidth memory, data-center capacity, co-packaged optics and PCIe Gen 6 all sit on the 90-day and 30-day decliner lists — even as Merck raises Electronics guidance on AI demand. That does not make Merck wrong; its exposure is materials and metrology, not GPUs. But it means the market may not pay up for the raise until the AI capex tape stabilizes. Meanwhile Optronics remains a drag: consumer electronics demand is suppressed by high memory prices, and management expects a more pronounced Q4 decline there. Electronics is really two businesses — a cyclical-up advanced-nodes franchise and a weak consumer-facing optics franchise.Life Science: Process Solutions is fine; the order trend is the question
Life Science organic growth was 6.1%, or 7.3% excluding tariff refunds to customers. Process Solutions grew 10.5% (12.6% underlying) with book-to-bill above 1 year-to-date. But Jean-Charles Wirth guided Q4 Process Solutions to mid-single-digit organic growth "due to a phasing effect" — a deliberate deceleration after a very strong nine months. The company keyword phasing effect captures it precisely. More important is what has quietly disappeared: in August Wirth warned that "if we have some inventory destocking effect, it may take place in 2027"; on this call he said lead times are back to normal (one to six months) and made no such warning. That is a soft positive the headline raise obscures. The bigger Life Science story is Bio-Techne. Helene von Roeder now expects it to add “close to 5% to group reported sales growth and about 10% to Life Science reported sales growth in 2027” — Helene von Roeder, CFO or Finance Executive · 2026-11-12, and 2026 guidance already includes one month of December contribution. The CDMO divestment to Lonza removes a sub-10%-of-Advanced-Solutions asset with below-sector margins; Silence Therapeutics adds Divesiran, a Phase III-ready siRNA in polycythemia vera. Leverage post-closing is now expected "clearly below" 3x net debt to EBITDA pre, better than the June projection. That is the strongest part of the quarter.Healthcare: a steeper Mavenclad cliff and a slipping Pergoveris
Healthcare is the problem child. Rare Diseases contributed to organic growth for the first time, with Ogsiveo up 25% and Gomekli up 80%, and desmoid tumor is now a top-10 company keyword. But Specialty Care deteriorated: U.S. Mavenclad sales fell almost 50% sequentially in Q3, and guidance now assumes zero U.S. Mavenclad sales from November. Beckmann was blunt:The Healthcare EBITDA pre margin is expected to decline from here, though management remains committed to north of 30%. The second disappointment is Pergoveris. In November 2025 Danny Bar-Zohar said the company was “working towards a launch of Pergoveris in the U.S. in the second half of 2026 under the Commissioner's National Priority Review Voucher Program” — Danny Bar-Zohar, Executive · 2025-11-13. On this call: “we are still under review. We are collaborating with the FDA, and we are expecting a decision in the coming months.” — Danny Bar-Zohar, Executive · 2026-11-12 The CNPV has not expired and the file was accepted, but the H2 2026 U.S. launch is now at risk — and Pergoveris is the growth engine of the Fertility franchise. Management also formally walked away from its Lp(a) asset after the Novartis pelacarsen HORIZON readout, a rare public admission of pipeline pruning.It's only fair to assume a rather steep Mavenclad decline in 2027.